Epithalon

Epithalon is a synthetic tetrapeptide derived from pineal gland extract, associated with telomere elongation, anti-aging, and sleep regulation; in practice, sleep and circadian rhythm is what most people run it for, with a smaller longevity-focused thread. Community dosing runs from 250 mcg to 5 mg, most commonly 500 mcg daily, while clinician protocols run higher at 1 mg to 10 mg subcutaneously. The tradeoff to know up front: there is no FDA-approved indication, so all human use is off-label or compounded. Effects on sleep and dreams are the dominant reported experience, and not everyone finds them positive.

Half-life~3 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsno dataAnecdotalEfficacyAnecdotalSideEffectsPrice1.81.73.63.14.0

Measured on 5 of 6 axes

Research Evidence

Evidence shape

Epithalon possesses a low tier of clinical evidence, consisting entirely of exploratory human treatment studies rather than formal, registered clinical trials. While fourteen published studies exist, the research remains thin and lacks the rigor of blinded, large-scale investigations. The absence of any completed, registered trials means the current literature base is limited to preliminary observations, with no data available to support broader clinical applications or standardized therapeutic outcomes.

Depthhow much
0 registered trials
Breadthhow many areas
2 indications mapped
1 thin / exploratory · 1 animal-only
Qualityhow rigorous
No completed trials
Breadth and depth38 rows captured
Human
direct clinical signal
14
Animal
translational support
12
In vitro
mechanistic support
12
HighMediumLow

Anecdotal efficacy

1
Hong Kong
500 mg×10
$130.00
$0.26/mg
2
US
500 mg×10
$180.00
$0.36/mg
3
CN
500 mg×10
$202.00
$0.4/mg
4
unknown
500 mg×10
$240.00
$0.48/mg
5
US
100 mg
$59.99
$0.6/mg
6
--
10 mg
$7.50
$0.75/mg

price offers can be sorted by column · 20 out-of-stock offers not shown

1-6 of 251

EPITHALON dosing & protocol

How EPITHALON is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 14
Typical dose
100 mg
typical
0
20 mg
40 mg
60 mg
80 mg
100 mg
across 1 dosed source · darker = more agree
Frequency
daily
Route
subQ

Across the cited trials, the administered dose was consistently 100 mg given subcutaneously on a daily schedule, with no variation reported.

14 sources
Clinician practice
Doctor & published-protocol guidance · n = 3
Typical dose
5 mg1 mg – 10 mg
typical
0
20 mg
40 mg
60 mg
80 mg
100 mg
distribution of 5 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
subQ

Clinicians typically administer 5 mg of epithalon subcutaneously each day, with reported daily doses ranging from 1 mg to 10 mg; a once‑weekly 1 mg subcutaneous injection is also reported.

3 sources
Anecdotal
Community-reported real-world use · n = 52
Typical dose
500 µg100 µg – 50 mg
typical
0
20 mg
40 mg
60 mg
80 mg
100 mg
distribution of 58 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
subQ
Cycle
10 days on / 20 days off · 2 reports

Most reports list a dose of roughly 500 mcg without a stated schedule; a smaller group takes about 1 mg each day. Only two reports describe a 10‑day on / 20‑day off cycle.

52 sources

Related peptides